UCB Makes Another Push To Get Bimzelx Over Finishing Line In US
Potential Blockbuster Resubmitted For Psoriasis
Executive Summary
The Belgian group was stunned by an FDA rejection in May for its dual IL-17A and IL-17F inhibitor and although the refiling is complete, UCB may still have to wait six months to get Bimzelx into the all-important US psoriasis market.
You may also be interested in...
UCB Buoyant As Bimzelx Starts To Deliver
The Belgian drugmaker’s faith in the psoriasis drug is looking to be well placed and with other indications coming aboard, sales forecasts of around €5bn-6bn for the pipeline-in-a-product seem very achievable.
UCB Wins Two Key US Approvals: Bimzelx In Psoriasis, Zilbrysq In gMG
Two years after its first FDA review, UCB’s next blockbuster Bimzelx finally crossed the finish line. Supplemental filings for more indications will soon follow as the company forecasts €4bn in peak sales.
UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.